Journey Medical Corporation
NASDAQ:DERM · NASDAQ Capital Market
+$0.06 today
Vol 0.40M · Avg 0.28M
Management
Put operating results in leadership context
Review returns on capital, executive background, insider transactions, and growth quality to judge whether management is compounding value well.
Return Metrics
ROE, ROIC & ROA over time
ROE
-35.9%
avg 176.9%
ROIC
-14.3%
avg -31.7%
ROA
-12.1%
avg -24.6%
Analysis
ROA is currently the strongest return metric at -12.1% versus its period average of -24.6%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Tenure | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|---|
Claude Maraoui | Founder, President, Chief Executive Officer & Director | $950,230.00 | — | 59 | $2.44M | 8.85% |
Ramsey Alloush | Chief Operating Officer, General Counsel & Company Secretary | $591,984.00 | — | 40 | $62,795.00 | 0.23% |
Joseph Benesch | Chief Financial Officer & Corporate Controller | $436,951.00 | — | 59 | $261,371.00 | 0.95% |
Lindsay Allan Rosenwald | Executive Chairman | $50,000.00 | — | 71 | $211,146.00 | 0.77% |
Jaclyn Jaffe | Senior Director of Corporate Operations | — | — | — | — | — |
Louis Donati | Director of Market Access | — | — | — | — | — |
Robert Nevin | Chief Commercial Officer | — | — | 57 | $259,907.00 | 0.94% |
Insider Trading
SEC Form 4 transactions — last 12 months
No insider transactions in the last 12 months.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A1 analysts |
| Revenue | N/A | N/A | +79.7% | +15.6% (12yr)1 analysts |
| Net Income | N/A | N/A | N/A | N/A1 analysts |
| EBIT | N/A | N/A | N/A | N/A1 analysts |
Analysis
Recent growth has been strongest in Revenue at +79.7% over three years. Forward estimates point to Revenue at +15.6% (12yr), giving you a quick check on whether expectations are accelerating or cooling.
Competitors
Peer companies in the same sector
OraSure Technologies, Inc.
NASDAQ:OSUR
$299.38M
Cartesian Therapeutics, Inc.
NASDAQ:RNAC
$280.59M
Fennec Pharmaceuticals Inc.
NASDAQ:FENC
$256.08M
Orchestra BioMed Holdings, Inc.
NASDAQ:OBIO
$234.68M
Inventiva S.A.
NASDAQ:IVA
$184.28M
MediWound Ltd.
NASDAQ:MDWD
$153.38M
Organigram Global Inc.
NASDAQ:OGI
$136.55M
Solana Company
NASDAQ:HSDT
$93.42M
Nyxoah S.A.
NASDAQ:NYXH
$61.39M
China SXT Pharmaceuticals, Inc.
SXTC
$1.72M
Who manages DERM?
Journey Medical Corporation (DERM) lists 7 active executives. The top listed executive is Joseph Benesch, Chief Financial Officer & Corporate Controller.
Are DERM insiders buying or selling?
Recent insider activity shows net buying of $742.22M.
Explore More
Continue the stock analysis
Jump to another research area for this company.